Neuronal cholecystokinin and schizophrenia: pathogenic and therapeutic studies

C. A. Tamminga, R. L. Littman, L. D. Alphs, T. N. Chase, G. K. Thaker, A. M. Wagman

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Neuroleptic-free schizophrenic patients received caerulein, a potent analogue of cholecystokinin octapeptide, in a fixed- and rising-dose schedule. In addition, neuroleptic-treated patients received a single dose of the peptide with a 4-week follow-up. No significant change in mental status was observed after any of these administration schedules. Peak plasma levels of caerulein were noted at 20-30 min after IM administration; at this time no changes in cortical evoked potential were demonstrated. Furthermore, levels of cholecystokinin were not found to be reduced, but were in fact elevated in lumbar cerebrospinal fluid of schizophrenic patients. These data argue against the antipsychotic efficacy of systemic caerulein administration and, because evidence of CNS response to CCK is lacking, suggest that other pharmacologic strategies may be necessary to effectively modify central peptide systems with systemically administered drugs.

Original languageEnglish (US)
Pages (from-to)387-391
Number of pages5
JournalPsychopharmacology
Volume88
Issue number3
DOIs
StatePublished - Mar 1986

Fingerprint

Ceruletide
Cholecystokinin
Antipsychotic Agents
Schizophrenia
Appointments and Schedules
Sincalide
Peptides
Evoked Potentials
Cerebrospinal Fluid
Therapeutics
Pharmaceutical Preparations

Keywords

  • Caerulein
  • Cerebrospinal fluid
  • Cholecystokinin
  • Peptide pharmacology
  • Schizophrenia

ASJC Scopus subject areas

  • Pharmacology

Cite this

Tamminga, C. A., Littman, R. L., Alphs, L. D., Chase, T. N., Thaker, G. K., & Wagman, A. M. (1986). Neuronal cholecystokinin and schizophrenia: pathogenic and therapeutic studies. Psychopharmacology, 88(3), 387-391. https://doi.org/10.1007/BF00180843

Neuronal cholecystokinin and schizophrenia : pathogenic and therapeutic studies. / Tamminga, C. A.; Littman, R. L.; Alphs, L. D.; Chase, T. N.; Thaker, G. K.; Wagman, A. M.

In: Psychopharmacology, Vol. 88, No. 3, 03.1986, p. 387-391.

Research output: Contribution to journalArticle

Tamminga, CA, Littman, RL, Alphs, LD, Chase, TN, Thaker, GK & Wagman, AM 1986, 'Neuronal cholecystokinin and schizophrenia: pathogenic and therapeutic studies', Psychopharmacology, vol. 88, no. 3, pp. 387-391. https://doi.org/10.1007/BF00180843
Tamminga, C. A. ; Littman, R. L. ; Alphs, L. D. ; Chase, T. N. ; Thaker, G. K. ; Wagman, A. M. / Neuronal cholecystokinin and schizophrenia : pathogenic and therapeutic studies. In: Psychopharmacology. 1986 ; Vol. 88, No. 3. pp. 387-391.
@article{f08425b689b64862bcf52ff4279d90d2,
title = "Neuronal cholecystokinin and schizophrenia: pathogenic and therapeutic studies",
abstract = "Neuroleptic-free schizophrenic patients received caerulein, a potent analogue of cholecystokinin octapeptide, in a fixed- and rising-dose schedule. In addition, neuroleptic-treated patients received a single dose of the peptide with a 4-week follow-up. No significant change in mental status was observed after any of these administration schedules. Peak plasma levels of caerulein were noted at 20-30 min after IM administration; at this time no changes in cortical evoked potential were demonstrated. Furthermore, levels of cholecystokinin were not found to be reduced, but were in fact elevated in lumbar cerebrospinal fluid of schizophrenic patients. These data argue against the antipsychotic efficacy of systemic caerulein administration and, because evidence of CNS response to CCK is lacking, suggest that other pharmacologic strategies may be necessary to effectively modify central peptide systems with systemically administered drugs.",
keywords = "Caerulein, Cerebrospinal fluid, Cholecystokinin, Peptide pharmacology, Schizophrenia",
author = "Tamminga, {C. A.} and Littman, {R. L.} and Alphs, {L. D.} and Chase, {T. N.} and Thaker, {G. K.} and Wagman, {A. M.}",
year = "1986",
month = "3",
doi = "10.1007/BF00180843",
language = "English (US)",
volume = "88",
pages = "387--391",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Neuronal cholecystokinin and schizophrenia

T2 - pathogenic and therapeutic studies

AU - Tamminga, C. A.

AU - Littman, R. L.

AU - Alphs, L. D.

AU - Chase, T. N.

AU - Thaker, G. K.

AU - Wagman, A. M.

PY - 1986/3

Y1 - 1986/3

N2 - Neuroleptic-free schizophrenic patients received caerulein, a potent analogue of cholecystokinin octapeptide, in a fixed- and rising-dose schedule. In addition, neuroleptic-treated patients received a single dose of the peptide with a 4-week follow-up. No significant change in mental status was observed after any of these administration schedules. Peak plasma levels of caerulein were noted at 20-30 min after IM administration; at this time no changes in cortical evoked potential were demonstrated. Furthermore, levels of cholecystokinin were not found to be reduced, but were in fact elevated in lumbar cerebrospinal fluid of schizophrenic patients. These data argue against the antipsychotic efficacy of systemic caerulein administration and, because evidence of CNS response to CCK is lacking, suggest that other pharmacologic strategies may be necessary to effectively modify central peptide systems with systemically administered drugs.

AB - Neuroleptic-free schizophrenic patients received caerulein, a potent analogue of cholecystokinin octapeptide, in a fixed- and rising-dose schedule. In addition, neuroleptic-treated patients received a single dose of the peptide with a 4-week follow-up. No significant change in mental status was observed after any of these administration schedules. Peak plasma levels of caerulein were noted at 20-30 min after IM administration; at this time no changes in cortical evoked potential were demonstrated. Furthermore, levels of cholecystokinin were not found to be reduced, but were in fact elevated in lumbar cerebrospinal fluid of schizophrenic patients. These data argue against the antipsychotic efficacy of systemic caerulein administration and, because evidence of CNS response to CCK is lacking, suggest that other pharmacologic strategies may be necessary to effectively modify central peptide systems with systemically administered drugs.

KW - Caerulein

KW - Cerebrospinal fluid

KW - Cholecystokinin

KW - Peptide pharmacology

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=0022589157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022589157&partnerID=8YFLogxK

U2 - 10.1007/BF00180843

DO - 10.1007/BF00180843

M3 - Article

C2 - 3083460

AN - SCOPUS:0022589157

VL - 88

SP - 387

EP - 391

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 3

ER -